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Abstract
Introduction: The pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the
proliferation of estrogen receptor a (ERa)-positive breast cancer cell lines. Here, we investigated the role of
melatonin in the regulation of breast cancer cell invasion.
Methods: Three invasive MCF-7 breast cancer cell clones - MCF-7/6, MCF-7/Her2.1, and MCF-7/CXCR4 cells - were
employed in these studies. All three cell lines exhibited elevated phosphorylation of the ERK1/2 and p38 mitogen-
activated protein kinase (MAPK) as determined by Western blot analysis. The effect of melatonin on the invasive
potential of these human breast cancer cells was examined by matrigel invasion chamber assays. The expression
and proteinase activity of two matrix metalloproteinases (MMPs), MMP-2 and MMP-9, were analyzed by Western
blot analysis and gelatin zymography, respectively.
Results: Melatonin (10
-9 M) significantly suppressed the invasive potential of MCF-7/6 and MCF-7/Her2.1 cells as
measured by matrigel invasion chamber assays, and significantly repressed the proteinase activity of MMP-2 and
MMP-9. In MCF-7/CXCR4 cells, melatonin significantly inhibited stromal-derived factor-1 (SDF-1/CXCL12) induced
cell invasion and activity of MMP-9. Elevated expression of the MT1 melatonin receptor further enhanced, while
luzindole, an MT1/MT2 antagonist, abrogated melatonin’s anti-invasive effect, suggesting that melatonin’s effect on
invasion is mediated, principally, through the MT1 receptor. Furthermore, melatonin repressed the phosphorylation
of p38 MAPK in MCF-7/Her2.1 cells and blocked stromal-derived factor-1 (SDF-1) induced p38 phosphorylation in
MCF-7/CXCR4 cells. SB230580, a p38 inhibitor, was able to mimic, while transfection of the cells with a
constitutively-active MKK6b construct blocked melatonin’s effect on cell invasion, suggesting that the anti-invasive
action of melatonin is mediated through the p38 pathway.
Conclusions: Melatonin exerts an inhibitory effect on breast cancer cell invasion through down-regulation of the
p38 pathway, and inhibition of MMP-2 and MMP-9 expression and activity.
Introduction
Over the last several decades, melatonin’s growth-inhibi-
tory action in breast cancer has been studied extensively
both in vivo and in vitro. In contrast, only a minimal
amount of work has been done with regard to the role
of melatonin in breast cancer invasion and metastasis. It
has been observed in several early correlative studies
that the plasma level of melatonin is significantly
reduced in cancer patients with metastatic disease as
compared with those without metastases [1,2]. In 1998,
Cos and colleagues [3] reported that physiological con-
centrations of melatonin (10
-9 M) significantly reduced
the invasive capacity of MCF-7 human breast cancer
cells as measured by Falcon invasion chamber assays, a
modified Boyden chamber assay, and that melatonin
could enhance the expression of the adhesion proteins,
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administration has been shown to reduce the incidence
of metastases in several in vivo studies [4-6].
Collectively, these results suggest that melatonin may
exert an inhibitory influence on breast cancer cell inva-
sion and metastasis, possibly by decreasing cell attach-
ment to the basement membrane. However, there has
been no further exploration of melatonin’s anti-invasive
action and mechanism(s) since the work by Cos and col-
leagues in 1998. A major obstacle to a better under-
standing of melatonin’s role in breast cancer invasion
and metastasis is the lack of a cell line that exhibits a
strong invasive potential but that is also estrogen recep-
tor-alpha (ERa)-positive and melatonin-responsive. The
ERa-positive MCF-7 cell, which has been well charac-
terized and extensively used in the in vitro studies
examining melatonin’s anti-proliferative effect and
which has been shown to be responsive to melatonin-
mediated growth inhibition, is widely regarded as poorly
invasive. Thus, the standard MCF-7 breast tumor cell
line is not a good model for invasion/metastasis studies.
Unfortunately, the highly invasive ERa-negative MDA-
MB-231 cells are unresponsive to melatonin’sg r o w t h -
inhibitory actions and thus are not a reasonable model
to study melatonin’s actions on invasion. Therefore, an
alternative cell line that exhibits high invasive potential
but that still retains the melatonin responsiveness is
essential for a model system in which to study melato-
nin’s actions on breast cancer invasion.
Here, we have used three invasive breast cancer cell
lines. The MCF-7/6 cells were derived from parental
MCF-7 cells by selection for metastatic potential by
serial passaging in nude mice [7]. As compared with the
MCF-7/AZ line (a parental MCF-7 cell clone renamed
by the group of Marc Mareel, Gent University Hospital,
Gent, Belgium), MCF-7/6 cells are invasive in the chick
heart embryo invasion assay [7] and spontaneously
metastasize in nude mice after subcutaneous injection
[8]. These cells have been demonstrated to be ERa-
positive and progesterone receptor (PR)-positive.
A second cell line used in our studies is the MCF-7/
Her2.1 cell line, which has been stably transfected with
and overexpresses the wild-type human Her2/neu (C-
erbB2) receptor. According to previous studies, receptor
tyrosine kinase Her2/neu plays an important role in the
malignant progression of breast cancer [9]. Amplifica-
tion and overexpression of Her2/neu occur in approxi-
mately 15% to 30% of primary breast tumors and
correlate with the nodal metastases and poor prognosis
[10]. It was previously shown that Her2/neu overexpres-
sion in breast cancer cells frequently leads to hyper-
activation of mitogen-activated protein kinase (MAPK)
signaling pathways [11]. Moreover, overexpression of
Her2/neu not only induces the invasive capacity in
mammary epithelial cells but also promotes the invasive-
ness of breast cancer cells in vitro [12,13] and induces
metastasis in animal models [13,14]. Although the effect
of Her2/neu on metastasis is well documented, the
mechanism underlying the effect of Her2/neu on breast
cancer invasion and metastasis is not fully understood.
A recent study by Ke and colleagues [15] showed that,
in human mammary epithelial cells, expression and
activity of matrix metalloproteinase (MMP)-2 and
MMP-9, two members of the MMP family which play
an important role in the degradation of the extracellular
matrix, were upregulated in response to overexpression
of Her2/neu and that the regulation of MMP-2 and
MMP-9 by Her2/neu may be mediated through the p38
MAPK and PI3K (phosphoinositide 3-kinase) signaling
pathways. These results suggest that the effects of Her2/
neu on breast cancer cell invasion may impinge on tar-
get molecules to orchestrate the degradation of the
extracellular matrix through simultaneous activation of
multiple signaling pathways.
Also used in our studies is an MCF-7 clone (MCF-7/
CXCR4) that overexpresses the chemokine receptor
CXCR4, a recently described key regulator of breast can-
cer invasion and metastasis [16]. Through interaction
with its cognate ligand, the chemokine stromal-derived
factor-1 (SDF-1/CXCL12), CXCR4 is proposed to direct
homing of breast cancer cells to particular sites of
metastases [16]. It has been demonstrated that downre-
gulation of CXCR4 inhibits in vitro invasiveness of
breast cancer cell and blocks breast cancer metastasis in
vivo [17,18]. Several lines of evidence suggest that the
effect of the SDF-1/CXCR4 axis on cell invasion may
involve activation of multiple signaling pathways, includ-
ing the p38 MAPK pathway [19-21].
Although MCF-7/6, MCF-7/Her2.1, and MCF-7/
CXCR4 breast cancer cells acquire their malignant phe-
notypes through different mechanisms and approaches,
their invasive potential may be enhanced through activa-
tion of a common intracellular signaling pathway that
plays an essential role in regulating cancer cell invasion
and metastasis. According to previous studies [22-25],
the p38 MAPK is a central kinase in a common pathway
that plays an important role in breast cancer invasion
and metastasis by modulating the expression and activ-
ity of molecules involved in the degradation of extracel-
lular matrix (that is, MMP-2 and MMP-9). Additionally,
p38 MAPK has been reported to be activated by both
the Her2/neu and SDF-1/CXCR4 pathways [15,19-21].
Moreover, p38 MAPK activity has been shown to be
regulated by cAMP [26-30]. Considering the above
results and the fact that melatonin, via its MT1 receptor,
regulates the intracellular concentration of cAMP in
breast cancer cells [31], we hypothesize that melatonin
plays an inhibitory role in breast cancer cell invasion by
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Our results demonstrated that melatonin suppresses the
in vitro invasive potential of breast cancer cells by alter-
ing the phosphorylation ofp 3 8M A P Ka n dt h ed o w n -
stream activity of MMP-2 and MMP-9.
Materials and methods
Chemicals and reagents
All chemicals and tissue culture reagents were pur-
chased from Sigma-Aldrich (S t .L o u i s ,M O ,U S A ) .C e l l
culture medium, Dulbecco’s modified eagle medium
(DMEM)/F-12 (1:1), RPMI 1640, and fetal bovine serum
(FBS) were purchased from Gibco BRL (now part of
Invitrogen Corporation, Carlsbad, CA, USA). The
FuGENE 6 transfection reagent was purchased from
Roche (Indianapolis, IN, USA). SDF-1/CXCL12 was pur-
chased from Research Diagnostics Inc. (now part of Fitz-
gerald Industries International, Acton, MA, USA).
Cell lines and cell culture
Eight human breast cancer cell lines were used in these
studies. The MDA-MB-231 human breast cancer cell
was purchased from American Type Culture Collection
(Manassas, VA, USA). The parental MCF-7 cell was
obtained from the laboratory of the late William L
M c G u r i e( S a nA n t o n i o ,T X ,U S A ) .T h eM C F - 7 / 6a n d
MCF-7/AZ (control MCF-7 cell for MCF-7/6) cells were
kindly provided by Marc Mareel. The MCF-7/Her2.1
(stably transfected with Her2/neu in pcDNA3.1 vector
and overexpresses wild-type Her2/neu) and its control
cell MCF-7/vec were generously provided by Frank E
Jones (Tulane University, New Orleans, LA, USA). The
MCF-7/CXCR4 cell line (stably transfected with CXCR4
in pcDNA3 vector and overexpresses CXCR4) and its
control counterpart MCF-7/pcDNA3 were gifts from
Matthew E Burow (Tulane University, New Orleans, LA,
USA). All cell lines, except MCF-7/6 and MCF-7/AZ,
were cultured in RPMI 1640 medium supplemented
with 10% FBS (Gibco BRL), 50 mM minimum essential
medium non-essential amino acids, 1 mM sodium pyru-
vate, 2 mM glutamine, 10 mM basal medium eagle, 100
mg/mL streptomycin, and 100 U/mL penicillin. The
MCF-7/6 and MCF-7/AZ cells were cultured in
DMEM/F-12 (1:1) with the same supplements described
above. These cell lines were routinely maintained at 37°
C in a humidified atmosphere of 5% CO2 and 95% air.
Total RNA extraction and reverse transcriptase-
polymerase chain reaction analysis
Reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis was performed to confirm the overexpres-
sion of MT1 in MT1-transfected cells. Total cellular
RNA was isolated using the TRIzol reagent (Invitrogen
Corporation) in accordance with the manufacturer’s
instructions. Reverse transcription was performed on 1
μg of total RNA using Superscript II RNase H- reverse
transcriptase (Invitrogen Corporation) and 200 ng ran-
dom hexadeoxynulceotide primers in 20-μL reaction
volumes containing 3 mM MgCl2, 10 mM DTT, 75 mM
KCl, and 0.5 mM dNTP. The polymerase chain reaction
(PCR) amplification was conducted using primer sets as
previously described [32]. Aliquots of the PCR products
were separated on a 1% agarose gel.
Real-time reverse transcriptase-polymerase chain reaction
analysis
Real-time RT-PCR was performed to determine the
mRNA levels of MMP-9 in MCF-7 cells transiently
transfected with CAMKK6b. Total cellular RNA was iso-
lated using the PerfectPure RNA Cultured Cell Kit (5
Prime, Gaithersburg, MD, USA) in accordance with the
manufacturer’s instructions. Reverse transcription was
performed on 1 μgo ft o t a lR N Au s i n gS u p e r s c r i p tI I
RNase H- reverse transcriptase (Invitrogen Corporation)
and 200 ng random hexadeoxynulceotide primers in 20-
μL reaction volumes containing 3 mM MgCl2,1 0m M
DTT, 75 mM KCl, and 0.5 mM dNTP. Real-time PCR
was carried out in 20 μL of PCR mixture containing 10
μL of 2× iQ SYBR Green Supermix and 1 μL of each
cDNA sample on an iCycler iQ real-time detection sys-
tem (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in
triplicates and recorded in real time and analyzed using
the accompanying program (iCycler iQ real-time PCR
detection system software, version 3.0A; Bio-Rad
L a b o r a t o r i e s ,I n c . ) .T h el e v e lo ft h e1 8 sr i b o s o m a lR N A
was also determined by real-time RT-PCR in each
cDNA sample to normalize the expression of MMP-9.
The primers used were as follows: human MMP-9: for-
ward primer, 5’-TGACAGCGACAAGAAGTG-3’,a n d
reverse primer, 5’-CAGTGAAGCGGTACATAGG-3’;
18s ribosomal RNA: forward primer, 5’-TTGACGGAA
GGGCACCACCAG-3’, and reverse primer, 5’-GCACCA
CCACCCACGGAATCG-3’. Melt curve analysis was
performed at the end of each PCR to confirm the speci-
ficity of the PCR product. Threshold cycle (Ct) values of
MMP-9 among samples were compared after correction
for 18s expression. The ratio of MMP-9 versus the cor-
responding 18s of each sample was determined on the
basis of the equation MMP-9/18s = 2
Ct(18s) - Ct(MMP-9).
The ratio of MMP-9/18s was compared among samples,
and the fold change of MMP-9 expression was obtained
by setting the values from vector-transfected cells to 1.
Cell proliferation assay
For melatonin response studies, MCF-7, MCF-7/AZ,
MCF-7/6 cells, MCF-7/vec, MCF-7/Her2.1, and MDA-
MB-231 cells were seeded at a density of 2.0 × 10
4 cells
per well, serum-starved for 24 hours, and treated with
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-9 M), or diluent (0.00001% ethanol), in
complete medium supplemented with 10% FBS. Cells
were counted after 6 days of melatonin exposure on a
hemacytometer using trypan blue to select for viable cells.
Protein extraction and Western blot analysis
Cells were harvested and then lysed in a protein extraction
buffer containing Tris (50 mM, pH 7.4), EDTA (20 mM),
NP-40 (0.5%), NaCl (150 mM), phenylmethylsulfonyl
fluoride (0.3 mM), NaF (1 mM), NaVO4 (1 mM), dithio-
threitol (1 mM), aprotinin (1 μg/mL), leupeptine (1 μg/
mL), and pepstatin (1 μg/mL). The cell lysates were centri-
fuged for 10 minutes at 10,000 g at 4°C. Protein concentra-
tions of the supernatants were determined using a protein
assay kit (Bio-Rad Laboratories, Inc.). Total protein (50 μg
per sample) was electrophoretically separated on a 10%
SDS-polyacrylamide gel and electroblotted onto a Hybond
membrane. After incubation with 5% non-fat milk in Tris-
buffered saline containing 0.1% Tween, the immunoblots
were probed with antibodies to MT1, Her2/neu (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), CXCR4
( A b c a m ,C a m b r i d g e ,M A ,U S A ) ,p h o s p h o - p 3 8( T h r 1 8 0 /
Tyr182), phospho-p44/42 MAPK (Thr202/Tyr204) (Cell
Signaling Technology, Inc., Danvers, MA, USA), MKK6
(Millipore Corporation, Billerica, MA, USA), or phospho-
ETS1 (Thr38) (Invitrogen Corporation). The same blots
were stripped and reprobed with antibodies to b-actin
(Sigma-Aldrich), p38, p44/42 MAPK (Cell Signaling Tech-
nology, Inc.), GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase), or ETS1 (Millipore Corporation), respectively.
For MMP-2 and MMP-9 expression studies, the enriched
conditioned medium from each treatment group was elec-
trophoretically separated on a 10% SDS-polyacrylamide
gel, and the blots were probed with anti-MMP-2 and anti-
MMP-9 antibodies (Chemicon, now part of Millipore
Corporation).
Transient transfection
MCF-7/6 or MCF-7/Her2.1 cells were seeded in 150-
mm
2 cell culture flasks at a density of 3.16 × 10
6 cells
per flask in DMEM/F-12 (1:1) medium or RPMI-1640
supplemented with 10% FBS. After 24-hour serum star-
vation, cells were then transfected with 7.9 μgo f
pcDNA3.1-MT1 or pcDNA3.1 empty vector or with 7.9
μg of CA-MKK6b (a dominant-positive MKK6b con-
struct provided by Matthew E Burow) or pcDNA3
empty vector, using the FuGENE 6 transfection reagent.
Twenty-four hours following transfection, these cells
were seeded for matrigel invasion assays.
Matrigel invasion chamber assay
The invasive potential of breast cancer cells was
assessed in vitro in matrigel-coated invasion Chambers
(BD BioCoat Matrigel Invasion Chamber; Becton
Dickinson Biosciences, Franklin Lakes, NJ, USA) in
accordance with the manufacturer’s instructions. Briefly,
cells in log phase of growth were serum-starved for 24
hours prior to seeding, detached by brief trypsinization,
and resuspended in medium containing the appropriate
treatment. The matrigel invasion inserts were rehydrated
and prepared as described in the manufacturer’s instruc-
tions. Cells (5 × 10
4 cells/mL in 0.5 mL serum-free
medium) were added in suspension to the upper cham-
ber, and medium (0.75 mL, supplemented with 10% FBS
as chemoattractant) containing the same treatment was
added to the bottom well. After incubation for 4 or 6
days, the non-invasive cells were removed from the
upper surface of the membrane, and the invasive cells
on the under surface of the membrane were stained
with a Diff-Quick staining kit (Dade Behring, now part
of Siemens Healthcare Diagnostics, Deerfield, IL, USA)
and counted microscopically at 100× magnification. Five
fields per membrane were randomly selected and
counted in each group. The percentage of invasive cells
w a sc a l c u l a t e da st h ep e r c e n t a g ei n v a s i o nt h r o u g ht h e
matrigel membrane relative to the migration through
the control membrane, as described in the manufac-
turer’s instructions. Because Cos and colleagues [3]
reported that treatment of MCF-7 cells with melatonin
for 6 days reduced cell invasion, we first confirmed their
results by incubating the cells for 4 or 6 days (as
described above) when examining melatonin’se f f e c to n
the invasion of MCF-7/6 and MCF-7/Her2.1 cells.
These results were confirmed in the more common 2-
day invasion assays (data not shown). In these assays,
the underside of the membrane was pre-coated with
fibronectin (20 ng/mL, as chemoattractant) for 1 hour at
37°C after rehydration, and the cells were seeded at a
higher density (2 to 3 × 10
6 cells/mL) and incubated for
2 days. As similar results were obtained using these dif-
ferent time frames, we chose to employ the 2-day inva-
sion assays in our subsequent experiments.
Preparation of conditioned medium
MCF-7/6 or MCF-7/CXCR4 cells were cultured in
DMEM/F-12 (1:1) or RPMI-1640 (respectively) supple-
mented with 10% FBS until confluency. The cells were
washed with phosphate-buffered saline three times and
then incubated in serum-free medium containing the
appropriate treatments. The conditioned medium was
collected, and an equal amount of the medium (0.5 mL)
was concentrated approximately 10-fold by centrifuga-
tion at 14,000 g using Microcon YM-30 columns (Milli-
pore Corporation). The volume of the concentrated
medium was measured, and a normalized volume of it
(15 μL) was stored at -70°C until used for Western blot
analysis or gelatin zymography.
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The activity of MMP-2 and MMP-9 in the conditioned
medium was determined by gelatin zymography. Briefly, the
conditioned medium (15 μL per sample) was mixed with an
equal volume of 2 × SDS sample buffer (Invitrogen Cor-
poration) and subjected under non-reducing conditions to
SDS-polyacrylamide gel polymerized with 1 mg/mL gelatin.
Following electrophoresis, the gels were incubated in a
renaturing buffer (2.5% Triton X-100) with gentle agitation
to remove SDS and then incubated in a developing buffer
(50 mM Tris-HCl buffer, pH 7.4, and 10 mM CaCl2)
overnight at 37°C. Gels were then stained with SimplyBlue
SafeStain (Invitrogen Corporation) and destained in the
Gel-Drying solution (Invitrogen Corporation). Gelatinase
activity was visualized as clear bands against the blue-
stained background. Molecular sizes were determined from
mobility using gelatin zymography standards (Chemicon).
Statistical analysis
Data are represented as the mean ± the standard error
of the mean. The statistical significance at 95% confi-
dence level was determined by one-way analysis of var-
i a n c ef o l l o w e db yaS t u d e n tN e w m a n - K e u l spost hoc
test analysis using the Statview software (SAS Institute,
Inc., Cary, NC, USA).
Results
Characterization of MT1 expression and melatonin
responsiveness of a panel of human breast cancer cells
with various invasive potentials
Three invasive MCF-7 variants were used in our follow-
ing studies: the MCF-7/6, MCF-7/Her2.1, and MCF-7/
CXCR4 cell lines. Among these three cell lines, MCF-7/
Her2.1 is highly invasive as compared with parental
MCF-7 cells (sixfold elevated invasion); MCF-7/6 and
MCF-7/CXCR4 cells are moderately to highly invasive
as compared with MCF-7 cells showing changes in inva-
sive capacity by 2.6- and 4.9-fold, respectively (Figure
1a). Western blot analysis demonstrated that MT1 is
expressed in MCF-7, MCF-7/6, MCF-7/Her2.1, and
MCF-7/CXCR4 cells, although MCF-7/6 and MCF-7/
CXCR4 cells exhibit lower levels of MT1 protein than
MCF-7 and MCF-7/Her2.1 cells (Figure 1b). In addition,
melatonin treatment after 6 days significantly suppressed
cell growth (by 30% to 40%) in all cells examined except
the ERa-negative MDA-MB-231 cells, in which no
growth inhibition was observed (Figure 1c).
Phosphorylation of ERK1/2 and p38 MAPKs is
upregulated in human breast cancer cells with elevated
expression of the Her2/neu or CXCR4
Expression of the Her2/neu and CXCR4 receptor was
examined by Western blot analysis. MCF-7/Her2.1 cells
showed markedly enhanced expression of Her2/neu as
compared with MCF-7/vec cells. Interestingly, Her2/neu
expression was also elevated in MCF-7/6 cells as com-
pared with their parental cell line MCF-7/AZ (Figure 2a,
top). In addition, CXCR4 expression is elevated by
approximately twofold in MCF-7/CXCR4 cells as com-
pared with the MCF-7/pcDNA3 cell line (Figure 2b).
Figure 1 Melatonin responsiveness and MT1 receptor expression
of a panel of human breast cancer cells. (a) The relative invasive
potential of MCF-7, MCF-7/AZ, MCF-7/6, MCF-7/vec, MCF-7/Her2.1, and
M C F - 7 / C X C R 4b r e a s tc a n c e rc e l l s .D a t aa r ep r e s e n t e da sf o l do fc o n t r o l
(MCF-7, set as 1). *P < 0.05 versus MCF-7 cells. (b) Western blot analysis
of MT1 protein expression in MCF-7, MCF-7/CXCR4, MCF-7/Her2.1, and
MCF-7/6 cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
protein levels are shown as loading control. (c) Effect of melatonin on
cell proliferation in MCF-7, MCF-7/AZ, MCF-7/6, MCF-7/Her2.1, and
MDA-MB-231 cells. Cells were serum-starved for 24 hours and treated
with melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol).
Cell numbers were determined on day 6 by hemacytometer cell
count. Data are presented as percentage of mean cell count in vehicle-
treated cells (100%). One-way analysis of variance followed by Student
Newman-Keuls post hoc test analyses was used to determine
statistically significant differences in the cell number between
melatonin- and vehicle-treated groups. *P < 0.05 versus vehicle-treated
cells (n =3 ) .
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leads to upregulation of downstream MAPKs, we examined
the phosphorylation of extracellular signal-regulated kinase
1/2 (ERK1/2) and p38 MAPK by Western blot analysis.
Phosphorylation of ERK1/2 was elevated in MCF-7/Her2.1,
MCF-7/CXCR4, and MCF-7/6 cells by 2.8-, 2.4-, and
1.2-fold, respectively, as compared with their respective
control cells (Figure 2a, middle). Moreover, phosphoryla-
tion of p38 MAPK (Figure 2a, bottom) was markedly
elevated in MCF-7/CXCR4 and MCF-7/Her2.1 cells
(5.8- and 6.5-fold, respectively) as compared with their
respective control cell lines. The MCF-7/6 cells also exhib-
ited increased p38 phosphorylation (2.4-fold) as compared
with MCF-7/AZ cells.
Melatonin represses breast cancer cell invasion
Here, we examined the effect of melatonin on the in
vitro invasion of MCF-7/6, MCF-7/Her2.1, and MCF-7/
CXCR4 cells by matrigel invasion chamber assays. Mela-
tonin significantly repressed the invasive potential of all
three cell lines. In MCF-7/6 cells, melatonin (10
-9 M)
significantly suppressed cell invasion by 32% by day 4
and 71% by day 6 (control set as 100%). The same
concentration of melatonin inhibited the invasion of
MCF-7/Her2.1 cells by 72% by day 4 and 62% by day 6
(Figure 3a). In MCF-7/CXCR4 cells, treatment with 10
-9
M melatonin for 2 days significantly decreased cell inva-
sion (by 66%) (Figure 3b).
According to previous studies, invasion of CXCR4-
expressing breast cancer cells is enhanced in response to
SDF-1/CXCL12 [33]. To investigate whether melatonin
inhibits SDF-1-induced invasion of MCF-7/CXCR4 cells,
SDF-1 (300 ng/mL) was added to the bottom well of the
matrigel invasion chambers as a chemoattractant. SDF-1
increased the invasive potential of MCF-7/CXCR4 cells
by 100% as compared with the non-stimulated control
(no SDF-1 added to the bottom well and diluent-treated,
set as 100%), and this effect was completely blocked by
melatonin administration (Figure 3b).
MT1 receptor mediates melatonin’s action on breast
cancer cell invasion
We have previously reported that the MT1 but not the
MT2 receptor is expressed in MCF-7 cells [32] and that
MT1 mediates melatonin’s growth-suppressive effect in
MCF-7 cells [32,34,35]. We further examined whether the
anti-invasive effect of melatonin is also mediated through
the MT1 melatonin receptor. As shown in Figure 3c, mel-
atonin treatment induced a significantly enhanced inhibi-
tion of cell invasion (73%) in cells that are transiently
transfected with and that overexpress MT1 as compared
with sham-transfected and vector-transfected cells
(approximately 40% inhibition). Moreover, pre-treatment
of cells with luzindole, an MT1/MT2 antagonist, for 15
minutes prior to the addition of melatonin completely
abrogated melatonin’s anti-invasive effect (Figure 3d).
These results suggest that the anti-invasive action of mela-
tonin is mediated via the MT1 receptor.
Melatonin suppresses the expression and activity of
MMP-2 and MMP-9
To investigate whether melatonin regulates breast can-
cer cell invasion by altering the expression of MMPs,
particularly MMP-2 and MMP-9, we examined the
effect of melatonin on MMP-2 and MMP-9 protein
expression in the conditioned medium using MCF-7/6
cells. As determined by Western blot analysis, expres-
sion of MMP-9 and MMP-2 was reduced in response to
melatonin treatment (10
-9 M) (Figure 4a).
Figure 2 Elevated phosphorylation of ERK1/2 and p38 MAPK in
MCF-7/CXCR4, MCF-7/6, and MCF-7/Her2.1 cells. (a) Western blot
analysis of Her2/neu receptor (top), phospho-ERK1/2 (p-ERK1/2)
(middle), and phospho-p38 (p-p38) (bottom) in MCF-7/vec, MCF-7/
Her2.1, MCF-7/AZ, MCF-7/6, MCF-7/pcDNA3, and MCF-7/CXCR4
breast cancer cells. The band intensity of Her2/neu, phospho-p38,
and phospho-ERK1/2 was normalized to that of b-actin, total p38,
and ERK1/2, respectively, and expressed as fold of control (MCF-7/
vec, MCF-7/AZ, and MCF-7/pcDNA3, set as 1). (b) Western blot
analysis of CXCR4 expression in MCF-7/pcDNA3 and MCF-7/CXCR4
cells. Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
are shown as loading control. The band intensity of CXCR4 was
normalized to that of GAPDH and expressed as fold of control
(MCF-7/pcDNA3, set as 1). ERK1/2, extracellular signal-regulated
kinase 1/2; MAPK, mitogen-activated protein kinase.
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Page 6 of 14Figure 3 Melatonin, via MT1, suppresses the invasive potential of human breast cancer cells. (a) Effect of melatonin on the invasion of
MCF-7/6 and MCF-7/Her2.1 cells. Cells were plated onto matrigel invasion chambers after being serum-starved for 24 hours and treated with
melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol) for 4 and 6 days. Data are represented as percentage of control (100%). *P < 0.05
versus diluent-treated cells (n = 3). (b) Effect of melatonin on stromal-derived factor-1 (SDF-1)-induced invasion of MCF-7/CXCR4 cells. Cells were
treated with melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol) for 2 days with or without SDF-1 in the bottom chamber as
chemoattractant ((+)/(-) SDF-1, 300 ng/mL). Data are presented as percentage of control ((-) SDF-1, vehicle-treated cells, 100%). *P < 0.05 versus
diluent-treated cells (n = 3). (c) Effect of MT1 overexpression on melatonin-regulated invasion of MCF-7/6 cells. Cells were transiently transfected
with either pcDNA3.1 empty vector (V) or pcDNA3.1-MT1 plasmid (MT1) or were sham-transfected (P). Twenty-four hours later, cells were plated
onto matrigel invasion chambers and treated with melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol) for 4 days. Data are presented
as percentage of the sham-transfected diluent-treated control (100%). Reverse transcriptase-polymerase chain reaction analysis of MT1 expression
is shown to demonstrate the overexpression of MT1 in pcDNA3.1-MT1-transfected cells. *P < 0.05 versus sham-transfected vehicle-treated control
cells (P-Control); **P < 0.05 versus vector-transfected melatonin-treated cells (V-Mlt) (n = 3). (d) Effect of luzindole on melatonin-regulated
invasion of MCF-7/6 cells. Cells were treated with diluent (Control, 0.00001% ethanol), melatonin (Mlt, 10
-9 M), luzindole (LZD, 10
-8 M), or
luzindole (10
-8 M) for 15 minutes followed by melatonin (10
-9 M) treatment (LZD + Mlt) for 2 days. Data are presented as percentage of ethanol-
treated control (100%). *P < 0.05 versus vehicle-treated control cells; **P < 0.05 versus melatonin-treated cells (n = 3). One-way analysis of
variance followed by Student Newman-Keuls post hoc test analyses was used to determine statistically significant differences in the percentage
of invasive cells among different treatment groups.
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Page 7 of 14We further examined the effect of melatonin on the
activity of MMP-2 and MMP-9 by gelatin zymography.
As shown in Figure 4b, a significant (60%) decrease in
the activity of MMP-9 was observed in cells treated with
melatonin (10
-9 M) for 48 hours (control set as 100%).
Similarly, melatonin also induces a significant decrease
in MMP-2 activity (70%) at 48 hours.
Previous studies have shown that one of the mechan-
isms underlying SDF-1-induced cancer cell invasion is
activation of MMP-9 and MMP-2 [33]. Therefore, we
further investigated whether melatonin suppresses SDF-
1-induced MMP-9 and MMP-2 activity. As determined
by gelatin zymography, MMP-9 activity was significantly
increased (1.5-fold) after administration of SDF-1 (100
ng/mL) for 24 hours as compared with diluent-treated
control (set as 1-fold). The SDF-1-mediated induction of
MMP-9 activity was completely blocked by simultaneous
treatment with melatonin (Figure 4c). However, melato-
nin did not block SDF-1-induced MMP-2 activity (data
not shown).
Figure 4 Melatonin suppresses the expression and activity of MMP-2 and MMP-9 in human breast cancer cells. Conditioned medium
was collected and concentrated as described in Materials and methods. (a) Melatonin’s effect on the protein expression of MMP-2 and MMP-9.
MCF-7/6 cells were treated with melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol) for 48 hours. Expression of MMP-2 and MMP-9 in
the conditioned medium was analyzed by Western blot analysis using anti-MMP-2 and anti-MMP-9 antibody. (b) The effect of melatonin on the
activity of MMP-2 and MMP-9. MCF-7/6 cells were treated with melatonin (Mlt, 10
-9 M) or diluent (Control, 0.00001% ethanol) for 48 hours. The
gelatinase activity of MMP-9 and MMP-2 in the conditioned medium was determined by gelatin zymography. The band intensities of MMP-9
and MMP-2, respectively, are presented in the graph as percentages of control (set as 100%). *P < 0.05 versus diluent-treated control (n = 4).
(c) Effect of melatonin on stromal-derived factor-1 (SDF-1)-induced activity of MMP-9 in MCF-7/CXCR4 cells. MCF-7/CXCR4 cells were treated with
diluent (control, 0.00001% ethanol), SDF-1 (100 ng/mL), or melatonin (10
-9 M) and SDF-1 (100 ng/mL) simultaneously (Mlt + SDF-1) for 24 hours.
The gelatinase activity of MMP-9 in the conditioned medium was determined by gelatin zymography. The band intensity of MMP-9 is presented
in the graph as percentage of control (set as 100%). *P < 0.05 versus diluent-treated control; **P < 0.05 versus SDF-1-treated group (n = 3).
Figures in (a-c) are representative Western blots or gelatin zymograms of at least three independent studies, respectively. MMP, matrix
metalloproteinase.
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Page 8 of 14Melatonin’s anti-invasive actions are mediated through
the p38 MAPK pathway
To investigate whether the MAPKs, ERK1/2 and p38,
play a role in melatonin regulation of breast cancer
invasion, Western blot analyses were performed to
determine whether melatonin regulates the phosphoryla-
tion of ERK1/2 and p38 MAPK. Our results demon-
strate that melatonin treatment (10
-9 M) significantly
suppressed p38 phosphorylation in MCF-7/6 cells (Fig-
ure 5a) and in MCF-7/Her2.1 cells (data not shown).
The melatonin repression of p38 phosphorylation was
abrogated by a 45-minute pre-treatment with H89 (10
μM), a protein kinase A (PKA) inhibitor, suggesting that
the effect of melatonin on p38 phosphorylation is
mediated through PKA (Figure 5c). Furthermore, a
robust induction of p38 phosphorylation was observed
in MCF-7/CXCR4 cells after 2-minute stimulation with
S D F - 1( 1 0 0n g / m L ) ,w h i c hw a sb l o c k e db ya5 - m i n u t e
pre-treatment with melatonin (Figure 5b). Conversely,
melatonin treatment did not affect the phosphorylation
of ERK1/2 in MCF-7/6 cells (data not shown), suggest-
ing that the suppressive effect of melatonin on p38
phosphorylation is specific.
We subsequently conducted matrigel invasion cham-
ber assays to determine whether SB230580, a p38 inhibi-
tor, could mimic melatonin’sa c t i o no nt h ei n v a s i o no f
MCF-7/6 cells. Treatment of MCF-7/6 cells with mela-
tonin (10
-9 M) induced a significant (50%) reduction in
the invasive potential of MCF-7/6 cells as compared
with diluent-treated controls (ethanol, set as 100%).
Similarly, SB230580 significantly inhibited the invasion
of MCF-7/6 cells (by 50%) compared with diluent-trea-
ted group (dimethyl sulfoxide) (Figure 5d).
The activity of p38 MAPK is regulated by the
upstream kinase, MKK6 [36]. To investigate whether
upregulation of p38 activity by transfection with a con-
stitutively active MKK6b DNA construct (CAMKK6b)
could reverse melatonin’s effect on MCF-7/Her2.1 cell
invasion, we conducted invasion assays and phosphory-
lation analyses of p38 by Western blot analyses. As
demonstrated in Figure 5e, p38 phosphorylation was
upregulated in CAMKK6b-transfected cells. In vector-
transfected cells, melatonin treatment significantly sup-
pressed cell invasion (by 70%) as compared with etha-
nol-treated control (set as 100%). In contrast, melatonin
did not have a significant effect on the invasive potential
of CAMKK6b-transfected cells (Figure 5e).
CAMKK6b upregulates MMP-9 mRNA expression and ETS1
phosphorylation
MMP-9 has been shown to be a target gene of the tran-
scription factor ETS1 [37]. There is evidence that p38
can phosphorylate and potentially activate ETS1 [38].
To investigate whether p38 regulates the transcription
of MMP-9, real-time RT-PCR analyses were performed
to determine the mRNA expression of MMP-9 in MCF-
7 cells transiently transfected with CAMKK6b. As
shown in Figure 6a, MMP-9 mRNA levels were signifi-
cantly increased in CAMKK6b-transfected cells as com-
pared with vector-transfected cells. This induction of
MMP-9 mRNA expression was accompanied by an
increase in the phosphorylation of ETS1 as determined
by Western blot analyses (Figure 6b).
Discussion
To define the role of melatonin in breast cancer cell
invasion and metastasis, we used three invasive breast
cancer cell clones that were derived from the parental
MCF-7 cells - the MCF-7/6, MCF-7/Her2.1, and MCF-
7/CXCR4 cells - instead of using the poorly invasive
MCF-7 breast cancer cells. These three cell clones were
selected because they are highly invasive and metastatic
as compared with the parental MCF-7 cells while still
retaining many characteristics of the parental MCF-7
cells.
As shown in Figure 1, MT1 is expressed at the protein
level in all three cell lines, with MCF-7/Her2.1 cells
exhibiting highest level of MT1. In addition, both MCF-
7/6 and MCF-7/Her2.1 cells are responsive to melato-
nin’s growth-suppressive effect, with melatonin (10
-9 M)
showing equal effectiveness in suppressing the growth of
these cells as it does in parental MCF-7 cells (Figure 1).
When it comes to the ability to invade and metastasize,
MCF-7/6, MCF-7/Her2.1, and MCF-7/CXCR4 cells all
exhibited elevated invasive potential as compared with
the parental MCF-7 cells.
The enhanced invasive potential in MCF-7/Her2.1 and
MCF-7/6 cells, respectively, may be a direct result of
Her2/neu overexpression. According to previous reports,
overexpression of Her2/neu and constitutive activation
of the Her2/neu signaling pathway can constitutively
activate MAPK [11] while promoting breast cancer cell
invasion and metastasis [12-14]. As expected, expression
of Her2/neu is markedly upregulated in MCF-7/Her2.1
cells that have been transfected with the wild-type
Her2/neu. Interestingly, Her2/neu is also overexpressed
in MCF-7/6 cells that have been selected for metastatic
potential by serial passaging in nude mice. These data
suggest that upregulation of the Her2/neu pathway may
be one of the early events in the progression toward
invasiveness.
Although the precise mechanisms by which the Her2/
neu pathway regulates breast cancer invasion and metas-
tasis are not yet fully understood, it has been suggested
that multiple signaling pathways, including ERK1/2 and
p38, act as the downstream effectors to promote the
invasive potential of these breast cancer cells [15].
Therefore, it is possible that MCF-7/Her2.1 and MCF-7/
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Page 9 of 14Figure 5 The anti-invasive effects of melatonin are mediated through the p38 MAPK signaling pathway. (a) The effect of melatonin on
the phosphorylation of p38 MAPK. MCF-7/6 cells were serum-starved for 24 hours and treated with diluent (Control, 0.00001% ethanol) or
melatonin (Mlt, 10
-9 M) for 30 minutes in fresh medium supplemented with 10% fetal bovine serum. Expression of phospho-p38 (p-p38) and
total p38 (p38) was analyzed by Western blot analysis. (b) The effect of melatonin on stromal-derived factor-1 (SDF-1)-induced p38
phosphorylation. MCF-7/CXCR4 cells were serum-starved for 48 hours and pre-treated with melatonin (10
-9 M) or diluent (0.00001% ethanol) for
5 minutes followed by SDF-1 (100 ng/mL) stimulation for 2 minutes (Mlt + SDF-1). (c) The effect of H89 on melatonin regulation of p38
phosphorylation. MCF-7/6 cells were serum-starved for 24 hours and pre-treated with H89 (10 μM) for 45 minutes followed by a 30-minute
treatment with melatonin (10
-9 M). Figures in (a-c) are representative Western blots from three independent studies, respectively. In (a) and (c),
the band intensity of phospho-p38 was normalized to that of total p38 and expressed in the graph as percentage of control (set as 100%).
*P < 0.05 versus diluent-treated control (n = 3). (d) The effect of SB230580 on the invasive potential of MCF-7/6 breast cancer cells. MCF-7/6 cells
were plated onto matrigel invasion chambers after 24-hour serum starvation and incubated in the medium containing diluent (ETOH, 0.00001%
ethanol; dimethyl sulfoxide, or DMSO), melatonin (Mlt, 10
-9 M), or SB230580 (20 μM). Data are presented as percentage of ethanol-treated control
(100%). *P < 0.05 versus ethanol-treated control cells. **P < 0.05 versus DMSO-treated control cells. (e) Effect of CAMKK6b on melatonin’s anti-
invasive action. MCF-7/Her2.1 cells were transiently transfected with empty vector (V) or CAMKK6b plasmid for 24 hours, plated onto matrigel
invasion chambers, and treated with diluent (Control, 0.00001% ethanol) or melatonin (Mlt, 10
-9 M) for 2 days. Data are presented as percentage
of vector-transfected diluent-treated control (100%). *P < 0.05 versus vehicle-treated control cells. Phosphorylation of p38 MAPK (p-p38) in
vector- and CAMKK6b-transfected cells was analyzed by Western blot analysis. Expression of total p38 (p38) was used as loading control. MAPK,
mitogen-activated protein kinase.
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Page 10 of 146 cells acquire their invasive capacities through Her2/
neu-induced constitutive activation of ERK1/2 and p38
MAPK. Recent studies have revealed that the chemokine
receptor CXCR4 also plays a critical role in the regulation
of breast cancer cell invasion and metastasis [16-18].
The molecular mechanisms underlying the action of
CXCR4 on breast cancer cell invasion are currently
under intense investigation. Given that activation of
CXCR4 leads to activation of multiple signaling path-
ways, including ERK1/2 and p38, in several cell types
[19-21], MCF-7/CXCR4 cells may acquire their invasive-
ness and metastatic potential through CXCR4-mediated
upregulation of the ERK1/2 and p38 MAPK signaling
pathways.
To define the role of melatonin in breast cancer cell
invasion, the effects of melatonin on breast cancer cell
invasion were tested on MCF-7/6, MCF-7/Her2.1, and
MCF-7/CXCR4 cells by in vitro matrigel invasion cham-
ber assays. In agreement with the data reported by Cos
and colleagues [3], we have demonstrated that melatonin,
at physiological concentrations (10
-9 M), significantly
inhibits the invasion of MCF-7/6, MCF-7/Her2.1, and
MCF-7/CXCR4 breast cancer cells. Furthermore, melato-
nin blocked the SDF-1/CXCL12-induced invasive poten-
tial of MCF-7/CXCR4 cells. Melatonin’s anti-invasive
action is also reflected by its suppressive effects on the
expression of MMP-2 and MMP-9, two major MMPs
mediating the degradation of the extracellular matrix.
Several reports have indicated that melatonin regulates
the activity of MMP-9 during protection against ethanol-
induced gastric ulcer and endometriosis [39,40]. In our
study, melatonin treatment not only reduces the protein
expression but also represses the enzymatic activity of
MMP-2 and MMP-9. These results suggest that melato-
nin’s anti-invasive action is mediated, at least in part, by
diminishing the ability of breast cancer cells to degrade
the components of extracellular matrix by modulating
MMP-2 and MMP-9 expression and activity. Moreover,
previous studies have shown that the activities of MMPs
are regulated by a group of endogenous molecules,
namely, the tissue inhibitors of matrix metalloproteinase
(TIMPs) [41]. According to our unpublished data from
cDNA microarray analysis, TIMP-3 expression is upregu-
lated in melatonin-treated MCF-7 cells overexpressing
the MT1 receptor, suggesting that TIMP-3 may be
another target of melatonin’s anti-invasive action.
To delineate the signaling pathway(s) used by melato-
nin to affect the invasive capacity of breast cancer cells,
we first investigated whether melatonin’sa n t i - i n v a s i v e
action is an MT1 receptor-mediated event. We have
previously reported that the MT1 but not the MT2
receptor is expressed in MCF-7 cells [32] and that MT1
mediates melatonin’s growth-suppressive effect in MCF-
7 cells [32,34,35]. It appears that MT1 is also involved
melatonin’s anti-invasive actions. As demonstrated in
our studies, enhanced MT1 expression potentiated mel-
atonin-mediated inhibition of cell invasion in MCF-7/6
cells. In contrast, this inhibitory effect was abolished by
pre-treatment of the cells with luzindole, an MT1/MT2
Figure 6 CAMKK6b upregulates MMP-9 mRNA expression and
ETS1 phosphorylation. (a) Effect of CAMKK6b on MMP-9 mRNA
expression. MCF-7 cells were transiently transfected with empty
vector or CAMKK6b plasmid for 24 hours. Real-time reverse
transcriptase-polymerase chain reaction (RT-PCR) analyses were
performed to examine the expression of MMP-9 mRNA in vector-
and CAMKK6b-transfected MCF-7 cells. The MMP-9 mRNA
expression was normalized to levels of 18s ribosomal RNA. *P < 0.05
versus vector-transfected cells. The figure is a representative real-
time RT-PCR analysis from three independent studies. (b) Effect of
CAMKK6b on ETS-1 phosphorylation. MCF-7 cells were transiently
transfected with empty vector or CAMKK6b plasmid.
Phosphorylation of ETS1 (p-ETS1) in vector- and CAMKK6b-
transfected cells was analyzed by Western blot analysis. Expression
of total ETS1 (t-ETS1) was used as loading control. The figure is a
representative Western blot from three independent studies. MMP,
matrix metalloproteinase.
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Page 11 of 14antagonist. The above data suggest that melatonin’s
anti-invasive action is mediated, at least in part, through
the G-protein-coupled MT1 receptor.
A well-established key intracellular signaling pathway
downstream of the MT1 receptor is the cAMP/PKA path-
way. As we previously reported, the MT1 receptor, by cou-
pling to Gi proteins upon melatonin binding, blocks the
accumulation of cAMP and potentially inhibits the activity
of PKA in MCF-7 cell [31]. Considering that the cAMP/
PKA pathway cross-talks with diverse signaling pathways,
including the ERK1/2 and p38 MAPK, and drawing
inspiration from our observation that constitutive activa-
tion of ERK1/2 and p38 MAPK appears to be the driving
force to promote the invasion of MCF-7/6, MCF-7/
CXCR4, and MCF-7/Her2.1 cells, we hypothesized that
melatonin inhibits the invasion of these cells by interacting
with the ERK1/2 and p38 MAPK pathways.
Melatonin regulation of MAPKs has been observed in
several cell types, including the COS-7 cell and brain tis-
sue, where melatonin has been reported to increase the
phosphorylation of ERK1/2 and JNK (c-Jun N-terminus
kinase) [42,43]. In human adult mesenchymal stem cells,
the phosphorylation of MEK1/2 and ERK1/2 is increased
by acute melatonin exposure but is inhibited by the long-
term melatonin administration [44]. However, our stu-
dies show that the anti-invasive action of melatonin is
mediated through the p38 MAPK pathway and not the
ERK1/2 pathway since melatonin treatment (10
-9 M)
repressed p38 phosphorylation in both MCF-7/6 (Figure
5 a )a n dM C F - 7 / H e r 2 . 1( d a t an o ts h o w n )b r e a s tc a n c e r
cells but had no effect on ERK1/2 phosphorylation (data
not shown). Furthermore, the p38 inhibitor, SB230580,
mimicked melatonin’s effect on cell invasion, significantly
reducing the invasive potential of the MCF-7/6 cells
Figure 7 Model of melatonin regulation of breast cancer cell invasion. Ligand-dependent activation of the membrane-associated G-protein-
coupled receptor MT1 leads to coupling of Gi2 protein to MT1 receptor. As a result, the Gai2 subunit dissociates from the Gbg subunits and
inhibits the activity of adenylcyclase (AC), and this leads to a decrease in the intracellular level of cAMP and inhibition of protein kinase A (PKA)
activity. The cAMP/PKA pathway cross-talks with the p38 pathway through PKA. In response to the reduced cAMP level, activity of p38 is
suppressed, and this causes further downregulation of MMP-9 expression via repression of ETS1 transcriptional activity and, potentially,
downregulation of MMP-2 transcription. MMP, matrix metalloproteinase.
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Page 12 of 14(Figure 5d), while expression of the constitutively active
MKK6b blocked melatonin’s effect on MCF-7/Her2.1 cell
invasion (Figure 5e).
Contrary to what we had expected, expression of
CAMKK6b did not significantly induce the invasive poten-
tial of MCF-7/Her2.1 cells. This may be due to the hyper-
activation of p38 MAPK in these Her2/neu-overexpressing
cells (6.5-fold elevated phosphorylation compared with
control cell line), which has reached a maximum for its
stimulatory effect on cell invasion such that further eleva-
tion of p38 activity beyond the maximum does not neces-
sarily lead to further increase in the invasive potential of
these already highly invasive breast cancer cells.
Several lines of evidence suggest that p38 MAPK regu-
lates the expression of MMP-9 [25,45]. We have shown
that expression of CAMKK6b leads to increased MMP-9
mRNA expression and elevated ETS1 phosphorylation in
MCF-7 cells (Figure 6). Given that MMP-9 is an ETS1
target gene [37], these results suggest that the MKK6/p38
pathway may regulate MMP-9 transcription through
phosphorylation and potentially activation of ETS1.
In summary, the above data suggest that melatonin, via
its MT1 receptor, plays an inhibitory role in breast cancer
cell invasion, possibly by specifically downregulating the
p38 MAPK signaling pathway. Although the precise
mechanism or mechanisms underlying melatonin’s action
on p38 MAPK remain unknown, one possibility is that
melatonin regulation of p38 phosphorylation is mediated
through Gi protein-induced changes in cAMP level and
PKA activity since melatonin’s effect on p38 phosphory-
lation is attenuated by PKA inhibitor H89 (Figure 5c).
In recent years, the p38 MAPK has emerged as a key
signaling molecule in the regulation of cancer invasion
and metastasis by modulating the expression and activity
of molecules governing the degradation of extracellular
matrix (that is, urokinase plasminogen activator, MMP-2,
and MMP-9) [22-25,45]. Our studies show that phosphor-
ylation of p38 MAPK, but not ERK1/2, is dramatically ele-
vated in both Her2/neu-overexpressing (MCF7/6 and
MCF-7/Her2.1) and CXCR4-overexpressing (MCF-7/
CXCR4) cells. These data indicate that, although MCF-7/
6, MCF-7/Her2.1, and MCF-7/CXCR4 cells acquire their
malignant phenotypes through different approaches, con-
stitutive activation of p38 MAPK may be a common
mechanism driving the transition of these cells from the
poorly/non-invasive phenotype to an invasive phenotype
(Figure 7). By inhibiting p38 phosphorylation, melatonin
has emerged as a promising anti-invasion factor that may
be useful in future cancer therapeutics in prevention not
only of breast cancer [46] but also of the ‘non-invasive-to-
invasive’ transition. In addition, cancer metastasis is a
multi-step event. Although our studies have clearly
demonstrated that melatonin significantly inhibits breast
cancer cell invasion in vitro, it is critical to further define
the role of melatonin in regulating breast cancer metasta-
sis in vivo to evaluate the clinical significance of melato-
nin’s anti-invasive effect.
Conclusions
In the present studies, we investigated the role of mela-
tonin in the regulation of breast cancer cell invasion.
Our results demonstrated that melatonin, via its MT1
receptor, plays an inhibitory role in breast cancer cell
invasion, possibly by specifically downregulating the p38
MAPK signaling pathway, and the downstream activity
of MMP-2 and MMP-9.
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